The high-CCL20 group contributed to a moderate risk increase with an HR of 1.99 (95% CI 1.21–3.29) (p = 0.007) regarding PFS in the advanced melanoma cohort, which is a stronger risk factor than elevated S100 at baseline (HR: 1.74, 95% CI: 1.05–2.90, p = 0.033) (Table 4). The gene discussed is CCL20; the disease is melanoma.